Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
September 17 2018 - 5:00PM
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine
company focused on developing and marketing products for wound
care, orthopedics, and sports medicine, announces that GrafixPL
PRIME™, a human placental membrane that can be stored at ambient
temperatures, launches for sale on October 1, 2018. The
structural matrix, growth factors, and cell viability of GrafixPL
PRIME is equivalent to those of Grafix®, a cryopreserved placental
membrane, but without the constraints of ultra-low temperature
storage.
GrafixPL PRIME is processed using Prestige LyotechnologySM,
which is Osiris’s preservation technique for ambient storage of
living tissues. GrafixPL PRIME is flexible and conforming and
designed as a wound cover/barrier for application directly to
hard-to-treat acute and chronic wounds, including but not limited
to diabetic foot ulcers, venous leg ulcers and thermal burns.
Jason Keefer, Interim President and CEO said: “I am pleased to
announce that our ambient temperature stable GrafixPL PRIME product
will be available in all settings of care, in addition to our
cryopreserved Grafix products. This allograft will preserve
the original characteristics of the fresh placental membrane that
support natural tissue repair process, but in contrast to
cold-stored cryopreserved tissues, GrafixPL PRIME is stored at
ambient temperature.”
About Osiris TherapeuticsOsiris Therapeutics,
Inc., based in Columbia, Maryland, researches, develops,
manufactures and commercializes regenerative medicine products
intended to improve the health and lives of patients and lower
overall healthcare costs. We have achieved commercial success
with products in orthopedics, sports medicine and wound care,
including the Grafix product line, Stravix®, BIO4® and Cartiform®.
We continue to advance our research and development by
focusing on innovation in regenerative medicine, including the
development of bioengineered stem cell and tissue‑based products.
Osiris®, Grafix®, GrafixPL®, GrafixPL PRIME™ Cartiform®, and
Prestige Lyotechnologysm are our trademarks. BIO4® is a trademark
of Howmedica Osteonics Corp., a subsidiary of Stryker Corporation.
More information can be found on the Company’s website,
www.Osiris.com. (OSIR-G)
Forward-Looking StatementsStatements herein
relating to the future of Osiris Therapeutics, Inc. and the ongoing
research and development of our products are forward-looking
statements. Osiris Therapeutics, Inc. cautions that these
forward looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under
the heading “Risk Factors” in the Osiris Therapeutics Inc. Annual
Report on Form 10-K for the years ended December 31, 2017, 2016 and
2015 and Quarterly Report on Form 10-Q for the quarters ended March
31, 2018 and June 30, 2018, as filed with the Securities and
Exchange Commission (SEC). We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. Examples of forward-looking statements
may include, without limitation, statements regarding the
anticipated efficiencies and advantages of products and the
likelihood of customer clinical adoption of any new products.
Although well characterized in scientific literature and
studies, preservation of tissue integrity, including cells, may not
be indicative of clinical outcome. Accordingly, you should
not unduly rely on these forward-looking statements. You are
encouraged to read our filings with the SEC, available at sec.gov,
for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak
only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our
business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and
uncertainties.
For additional information, please
contact:
Diane SavoieOsiris Therapeutics, Inc.(443)
545-1834OsirisPR@Osiris.com
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Osiris Therapeutics, Inc. (NASDAQ:OSIR)
Historical Stock Chart
From Apr 2023 to Apr 2024